Laser-Activated drug targets bladder tumors in early trial
NCT ID NCT05483868
First seen Nov 01, 2025 · Last updated Jun 21, 2026 · Updated 38 times
Summary
This early-stage trial is testing a new drug called belzupacap sarotalocan (AU-011) for people with non-muscle-invasive bladder cancer. The drug is injected directly into the tumor, sometimes with a laser to activate it. The main goal is to see if this approach is safe and feasible. About 55 participants will be enrolled.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for UROTHELIAL CARCINOMA BLADDER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Arkansas Urology
TERMINATEDLittle Rock, Arkansas, 72211, United States
-
Austin Health
RECRUITINGHeidelberg, Victoria, 3084, Australia
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Baylor College of Medicine
RECRUITINGHouston, Texas, 77030, United States
Contact Email: •••••@•••••
-
Carolina Urologic Research Center
RECRUITINGMyrtle Beach, South Carolina, 29272, United States
Contact Email: •••••@•••••
-
Hollywood Private Hospital
RECRUITINGNedlands, Western Australia, 6009, Australia
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Montefiore Medical Center
RECRUITINGThe Bronx, New York, 10461, United States
Contact Email: •••••@•••••
-
Penninsula Private Hospital
NOT_YET_RECRUITINGLangwarrin, Victoria, 3910, Australia
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Saint John's Cancer Institute
RECRUITINGSanta Monica, California, 90404, United States
Contact Email: •••••@•••••
-
The Royal Melbourne Hospital
NOT_YET_RECRUITINGParkville, Victoria, 3050, Australia
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
The University of Texas San Antonio
RECRUITINGSan Antonio, Texas, 78229, United States
Contact Email: •••••@•••••
-
The Urology Place
RECRUITINGSan Antonio, Texas, 78240, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Tower Urology
RECRUITINGLos Angeles, California, 90048, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Urology Associates, P.C.
SUSPENDEDNashville, Tennessee, 37209, United States
-
Urology Clinics of North Texas
RECRUITINGDallas, Texas, 75251, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Urology San Antonio/USA Clinical Trials
RECRUITINGSan Antonio, Texas, 78229, United States
Contact Email: •••••@•••••
-
Warringal Private Hospital
RECRUITINGHeidelberg, Victoria, Australia
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Westmead Private Hospital
RECRUITINGWestmead, New South Wales, 2145, Australia
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
belzupacap sarotalocan (AU-011) with or without laser activation
What this could lead to
If successful, this could point toward a new, targeted treatment for early-stage bladder cancer that may reduce the need for more invasive procedures.
What could go wrong
This is a very early Phase 1 trial with only 55 participants, focused on safety and feasibility. It is too soon to know if the treatment will be effective, and there may be side effects from the drug or laser.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.